BeyondSpring Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- BeyondSpring Inc. (NASDAQ: BYSI), a clinical-stage biopharmaceutical company, focuses on developing innovative cancer therapies through its Plinabulin pipeline and Targeted Protein Degradation (TPD) platform. The company develops Plinabulin, a selective immunomodulating microtubule-binding agent approved for preventing chemotherapy-induced neutropenia in the U.S. and China; Plinabulin in combination with docetaxel for non-small cell lung cancer (NSCLC) and epidermal growth factor receptor wild-type NSCLC following Phase III trials; Plinabulin with nivolumab (PD-1 antibody) after Phase I trials for NSCLC; Plinabulin with ipilimumab (CTLA-4 antibody) for extensive-stage small cell lung cancer (SCLC); Plinabulin with PD-1 or PD-L1 antibodies and radiation for various cancers; and Plinabulin with pembrolizumab, etoposide, and platinum for extensive-stage SCLC. It also advances three small molecule immune agents in preclinical stages and a drug discovery platform leveraging internal research and collaborations with the University of Washington on ubiquitination. BeyondSpring maintains an equity stake in SEED Therapeutics, a subsidiary it co-founded with Eli Lilly in 2020 focusing on molecular glue-based TPD therapies for oncology and neurodegeneration. Founded in 2010 and headquartered in Florham Park, New Jersey, the company operates globally with offices in Beijing and Dalian, China, and SEED offices in Pennsylvania; it targets patients with high unmet needs in immuno-oncology across the U.S., China, and other regions. Recent developments include the sale of a portion of its SEED Series A-1 Preferred Shares for $35.4 million in January 2025 to fund late-stage Plinabulin trials without equity dilution, retaining approximately 14.4% ownership alongside SEED Technology Limited; SEED's $30 million Series A-3 financing led by Eisai at a $100 million pre-money valuation in 2025, plus U.S. FDA and China NMPA IND clearances for its lead RBM39 degrader program; and SEED's finalist status for the 2025 Prix Galien USA Best Start-Up Award.
BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value
BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026
BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026
BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting
BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update
BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC Drugs
BeyondSpring (NASDAQ:BYSI) Stock Passes Above 50 Day Moving Average – Here’s Why
BeyondSpring Files 2025 Annual Report on Form 10-K
BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference
Financial Contrast: Lisata Therapeutics (NASDAQ:LSTA) vs. BeyondSpring (NASDAQ:BYSI)
Critical Review: Cyclerion Therapeutics (NASDAQ:CYCN) & BeyondSpring (NASDAQ:BYSI)
BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path
BeyondSpring Inc. (BYSI) 2025 Annual Shareholders Meeting (Transcript)
BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure
BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting
BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update
BeyondSpring Files 2024 Annual Report on Form 10-K
SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors
BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies
BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting